Mutations and dysregulation of FGFR2 are associated with several diseases, including cancers and genetic disorders. In cancer, FGFR2 has been found to be amplified or mutated in various types, such as breast and gastric cancer. Targeted therapies that inhibit FGFR2 signaling are being developed and have shown promise in clinical trials. Additionally, FGFR2 mutations are linked to skeletal disorders like Crouzon syndrome and Pfeiffer syndrome, which are characterized by craniosynostosis and limb abnormalities.
